Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemotherapy as Neoadjuvant for Advanced Endometrial Cancer
NCT06363708Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of tislelizumab in endometrial cancer (EC), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: R0 Resection Rate at 24 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06363708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363708.